Research

 

Selected Recent Publications

1. Klichko, V., Kaur, R.J., Archin, N., Lehrman, G, and Margolis, D.M. Hexamethylbisacetamide remodels the Human Immunodeficiency Virus type 1 promoter and induces Tat-independent HIV-1 expression without cellular activation. J. Virology, 2006; 80:4570–4579


2. Swindells, S, DiRienzo, G., Wilkin, T, Fletcher, C.V. Margolis, D.M., Thal, G.D., Godfrey, C., Bastow, B., Ray, M.G., Wang, H., Coombs, R.W., McKinnon, J., Mellors, J.W., for the AIDS Clinical Trials Group 5201 Study Team. A prospective, open-label pilot trial of regimen simplification to atazanavir/ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA. 2006; 296:806-14.


3. Busti, A.J., Tsikouris, T.P., Peeters, M.J., Das, S.R., Canham, R.M., Abdullah, S.M., and Margolis, D.M. A prospective evaluation of the effect of atazanavir on the QTc-interval and QTc-dispersion in HIV-positive patients. HIV Medicine 2006; 7:317-320.


4. Lehrman, G., Hogue, I.B., Palmer, S., Jennings, C., Spina, C.A., Wiegand, A., Landay, A.L., Coombs, R.W., Richman, D.D., Mellors, J.W., Coffin, J.M., Bosch, R.J., Margolis, D.M. Depletion of latent HIV infection in vivo. Lancet 2005; 36:549-555


5. Ylisastigui L., Kaur, R., Volker, J.L., Johnson, H., Hansen, U., and Margolis, D.M. Mitogen-Activated Protein Kinase Regulation of LSF Occupancy at the Integrated Promoter of HIV-1. J. Virology 2005; 79:5952-5962.


6. Kaur, R.J., Klichko, V., and Margolis, D.M. Ex vivo modeling of the effects of mycophenolic acid on HIV infection: considerations for antiviral therapy. AIDS Res. Hum. Retro. 2005; 21:116-124.


7. Ylisastigui L., Coull, J.J., Rucker V., Brodie, S.J., Bosch, R.J., Sodora, D., Dervan, P., and Margolis, D.M. Polyamides Reveal a Role for Repression in Viral Latency within HIV-infected Donors’ Resting CD4+ T Cells. J. Infectious Diseases. 2004; 190:1429-37.


8. Ylisastigui L., Lehrman, G., Bosch, R.J., and Margolis, D.M. Coaxing Human Immunodeficiency Virus Type 1 from Resting CD4+ T Cells: can the reservoir of HIV be purged? AIDS. 2004; 18:1101-1108


9. Coull, J.J., He, G., Melander, C., Rucker, V., Dervan, P.B., Margolis, D.M. Targeted Derepression of the Human Immunodeficiency Type 1 Long Terminal Repeat by Pyrrole-Imidazole Polyamides. J. Virology. 2002; 76:12349-54.


10. Margolis, D.M., Kewn, S., Coull, J.J., Ylisastigui, Y., Turner, D., Wise, H., Hossain, M. M., Lanier, E.R., Shaw, L.M., and Back, D.J. The Addition of Mycophenolate Mofetil to Antiretroviral Therapy Including Abacavir is Associated with Depletion of Intracellular Deoxyguanosine Triphosphate and a Decrease in Plasma HIV-1 RNA. J. Acquir Immune Defic Syndr. 2002; 31:45–49.


11. He, G. and Margolis, D.M. Counter-regulation of Chromatin Acetylation and Histone Deacetylase Occupancy at the Integrated Promoter of Human Immunodeficiency Virus Type 1 by the HIV-1 Activator Tat and the HIV-1 Repressor YY1. Molecular Cell. Biol. 2002; 22:2965-2973.

  People
  Publications
  Contact
 Home